VORANIGO is taken orally at the same time each day with or without food at home, at work, or wherever is best for your patients1
Recommended VORANIGO dosage for 30-day cycle
Adult patients:
- 40 mg orally once daily
Pediatric patients 12 years and older:
- Patients weighing ≥40 kg: 40 mg orally once daily
- Patients weighing <40 kg: 20 mg orally once daily
Continue VORANIGO until disease progression or unacceptable toxicity.
Take VORANIGO tablets at about the same time each day. If a dose is missed, take the missed dose as soon as possible within 6 hours. If a dose is missed by more than 6 hours, skip the missed dose, and take the next dose at the usual time.
If vomiting occurs after taking a dose, do not take a replacement dose, and take the next dose at the scheduled time on the following day.
VORANIGO tablets are supplied in two strengths: 40 mg or 10 mg tablets in 30-count bottles
Instruct your patients on how to take VORANIGO
Swallow tablets whole with water with or without food.
Do not split, crush, or chew tablets.
Treatment considerations for VORANIGO and recommended dosage reductions for adverse reactions (ARs)1
Initial assessment and monitoring liver laboratory tests
Before initiating VORANIGO:
- Evaluate blood chemistry and liver laboratory tests
- Verify pregnancy status in females of reproductive potential
During treatment with VORANIGO:
- The VORANIGO USPI does not include recommendations for electrocardiogram monitoring before or during treatment
Monitor liver laboratory tests (AST, ALT, GGT, total bilirubin, alkaline phosphatase) at the following intervals
Reduce the dose, withhold, or permanently discontinue VORANIGO based on severity
Pregnancy, fertility, family planning, and breast-feeding considerations1
- Based on animal embryo-fetal toxicity studies, VORANIGO can cause fetal harm when administered to pregnant women
- Based on findings in animals, VORANIGO may impair fertility in females and males of reproductive potential. The effects on female and male fertility were reversible in monkeys and were not reversible in rats. No fertility information is currently available for the use of VORANIGO in humans
- Advise females of reproductive potential to use effective nonhormonal contraception during treatment with VORANIGO and for 3 months after the last dose. VORANIGO can render some hormonal contraceptives ineffective
- Advise male patients with female partners of reproductive potential to use effective contraception during treatment with VORANIGO and for 3 months after the last dose
- Because of the potential for adverse reactions in breastfed children from VORANIGO, advise women not to breastfeed during treatment with VORANIGO and for 2 months after the last dose
The VORANIGO Patient Brochure can provide your patients with more information about dosing and treatment considerations
Recommended VORANIGO dosage reductions for ARs1
| Dose reduction | Recommended dose and schedule |
|---|---|
| Adult patients and pediatric patients 12 years and older weighing ≥40 kg | |
| First | 20 mg once daily |
| Second | 10 mg once daily |
| Pediatric patients 12 years and older weighing <40 kg | |
| First | 10 mg once daily |
| Permanently discontinue VORANIGO in patients unable to tolerate 10 mg once daily | |
Adjustments to treatment for ARs
Additional blood counts, including liver laboratory tests, and dose modifications may be recommended for increases in ALT, AST, and total bilirubin based on severity1
Recommended dose modifications and management for ARs1
Hepatotoxicity (Elevation of ALT or AST)
| Adverse reaction |
|
|||||||||||
| Hepatotoxicity (Elevation of ALT or AST) |
|
|||||||||||
| Other ARs |
|
|||||||||||
| Severitya | Management and dosage modifications |
|---|---|
| Grade 1 ALT or AST increase >ULN to 3 x ULN without concurrent total bilirubin >2 x ULN |
Continue VORANIGO at current dose Monitor liver laboratory tests weekly until recovery to <Grade 1 |
| Grade 2 ALT or AST >3 to 5 x ULN without concurrent total bilirubin >2 x ULN |
First occurrence: Withhold VORANIGO until recovery to ≤Grade 1 or baseline
Recurrence: Withhold VORANIGO until recovery to ≤Grade 1 or baseline, and resume VORANIGO at reduced dose
|
| Grade 3 ALT or AST >5 to 20 x ULN without concurrent total bilirubin >2 x ULN |
First occurrence: Withhold VORANIGO until recovery to ≤Grade 1 or baseline
Recurrence: Permanently discontinue VORANIGO
|
| Grade 2 or 3 ALT or AST >3 to 20 x ULN with concurrent total bilirubin >2 x ULN |
First occurrence: Withhold VORANIGO until recovery to ≤Grade 1 or baseline
Recurrence: Permanently discontinue VORANIGO
|
| Grade 4 Any ALT or AST >20 x ULN |
Permanently discontinue VORANIGO |
| Severitya | Management and dosage modifications |
|---|---|
| Grade 3 |
First occurrence: Withhold VORANIGO until recovery to ≤Grade 1 or baseline
Recurrence: Permanently discontinue VORANIGO
|
| Grade 4 | Permanently discontinue VORANIGO |
aAdverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
The VORANIGO Treatment Management Guide includes helpful information on VORANIGO dosing and administration, pharmacokinetics, drug-drug interactions and more
Dosage interruptions, reductions, and discontinuations in patients treated with VORANIGO in the INDIGO trial1
Dosage interruptions:
- Dosage interruptions of VORANIGO due to an AR occurred in 30% of patients
- ARs which required dose interruption in ≥5% of patients included ALT increased (14%), COVID-19 (9%), and AST increased (6%)
Discontinuations:
- ARs which resulted in permanent discontinuation of VORANIGO in ≥2% of patients included ALT increased (3%)
Dose reductions:
- Dose reductions of VORANIGO due to an AR occurred in 11% of patients
- ARs which required dose reduction in ≥5% of patients included ALT increased (8%)
Discontinuations:
- ARs which resulted in permanent discontinuation of VORANIGO in ≥2% of patients included ALT increased (3%)
